figshare
Browse
13045_2021_1120_MOESM1_ESM.docx (97.43 MB)

Additional file 1 of Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy

Download (97.43 MB)
Version 2 2021-09-24, 03:34
Version 1 2021-07-06, 03:33
journal contribution
posted on 2021-09-24, 03:34 authored by Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Additional file 1. Figure S1. PET/CT imaging for UPN1. Figure S2. Immunohistochemistry in tumor samples from all five patients. Figure S3. Biological biomarker detection from blood samples. Table S1. H-scores for PD-1 and PD-L1 in patients before CART19/20 therapy and after failure of CART19/20.

Funding

National Basic Research Program of China (973 Program) National Natural Science Foundation of China Fostering Funds from the Chinese PLA General Hospital’s National Excellent Young Scholar Science Fund

History

Usage metrics

    Journal of Hematology & Oncology

    Categories

    Keywords

    DLBCLAnti-PD-1CARTSalvage therapyPD-1/PD-L1

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC